Cell-Free Biomanufacturing Is About to Revolutionise How We Make Medicine

Cell-free protein production platforms can make vaccines and drugs without living organisms. Here is what this breakthrough means for vaccine manufacturing speed and cost.

Conventional pharmaceutical and vaccine manufacturing depends on living organisms — bacteria, yeast, mammalian cells in culture — as the biological machinery that produces therapeutic proteins, enzymes, and viral components. This biological dependence creates specific constraints: manufacturing facilities must maintain sterile cultures of living organisms under precise conditions, scale-up requires months to years as culture volumes are carefully increased, and any contamination event can destroy batches worth millions of dollars.

Cell-free biomanufacturing eliminates the living organism while retaining its molecular machinery. The approach extracts the specific cellular components needed to produce a target protein — ribosomes, energy generation systems, transcription and translation factors — and uses these cell-free extracts to produce the target protein directly from DNA instructions. Without the living cell, the system can be freeze-dried for storage and reconstituted on demand, operated at ambient temperature, and scaled without the culture maintenance that conventional manufacturing requires.

DARPA and NSF-funded researchers have built modular, freeze-dried cell-free systems specifically designed for the kind of distributed, rapid manufacturing that pandemic or biodefence scenarios require. A freeze-dried system that produces a specific protein can be shipped to a remote location, reconstituted with water, and produce doses within hours — compared to the months required to stand up conventional manufacturing capacity.

European companies including LenioBio are developing commercial cell-free platforms specifically for drug discovery applications. The specific drug discovery value is time: screening dozens of protein variants for binding affinity or enzyme activity, which requires producing each variant in sufficient quantities for testing, takes weeks with conventional manufacturing and hours with cell-free platforms.

For pandemic response: the COVID-19 vaccine manufacturing bottleneck — where demand enormously exceeded production capacity in 2021-2022 — was partly a reflection of the biological manufacturing constraints that cell-free platforms could reduce. A future pandemic scenario in which vaccine manufacturing can begin within days of sequence identification and scale without living cell culture constraints would fundamentally change the public health response curve.